#United States #New York #AVANT BIO #Maik Jornitz #Lukas Utiger

AVANT BIO Strengthens Operational Support and Strategic Growth

AVANT BIO, a growth equity firm focused on life sciences and enabling technologies, recently unveiled the addition of Maik W. Jornitz and Lukas Utiger to its advisory team. This strategic move aims to enhance operational support for portfolio companies while driving growth initiatives across various sectors.

As the life sciences landscape becomes increasingly complex, AVANT BIO’s commitment to nurturing its portfolio companies is underscored by its motto, “We Catalyze Value.” This approach is pivotal as it leverages the firm's extensive global network and operational expertise to propel companies towards scalability and sustainability. Jornitz and Utiger will not only serve as advisors but will also participate on the boards of various portfolio companies, ensuring that their insights contribute significantly to the business development and strategic directions of these firms.

A Closer Look at the New Advisors

Maik W. Jornitz

Maik Jornitz is a familiar name in bioprocessing and biomanufacturing, possessing over forty years of extensive experience in the industry. As the founder and principal consultant at BioProcess Resources LLC, he specializes in critical areas such as single-use technologies, sterile filtration, and bioprocessing facility design. His illustrious career includes a noteworthy 26-year tenure at Sartorius, culminating as Senior Vice President for Global Product and Marketing Management in Bioprocess. His subsequent role as CEO of G-CON Manufacturing saw him pioneer modular cleanroom infrastructure tailored for advanced therapeutics.

“Joining the exceptional team at AVANT BIO excites me greatly. Their dedication to growth and innovation in biopharma is inspiring and I look forward to supporting this dynamic journey,” expressed Jornitz. His credentials also highlight his leadership roles with the Parenteral Drug Association (PDA) and positions in various task forces, alongside board memberships with DIANT Pharma and Sunflower Therapeutics.

Lukas Utiger

Lukas Utiger, likewise, brings a wealth of knowledge with over thirty years of experience in executive leadership roles within the global CDMO and bioprocessing landscape. He has held prominent positions at Lonza Group AG, where he swiftly advanced through the ranks to become Chief Operating Officer of Lonza Life Science Ingredients and later, the President of Lonza Bioscience. Following his tenure at Lonza, he led DSM Pharmaceutical Products and DPx Fine Chemicals, eventually guiding the company through its merger with Patheon.

Utiger shared his enthusiasm, stating, “It’s a privilege to join the passionate team at AVANT BIO. My focus will be on fostering commercial scale-up for innovative technology startups, leveraging our significant experience to drive growth and efficiency.” He currently offers his consulting expertise through Utiger Life Science Consulting and is actively involved on the boards of Abzena, Aenova, and Sharp Packaging Services.

The Path Forward

The strategic appointments of Jornitz and Utiger highlight AVANT BIO’s goal to empower their portfolio companies actively. With the growing significance of enabling technologies in the healthcare sector, AVANT BIO is positioning itself to transform scientific innovations into successful commercial ventures. Daniella Kranjac, the Founding General Partner at AVANT BIO, remarked, “The operational experience that Maik and Lukas bring to the table is invaluable. Their established networks and success stories are precisely what our companies need to advance.”

AVANT BIO continues to pursue its mission of enhancing the development and delivery of groundbreaking therapies, ensuring that its portfolio not only meets market demands but also shapes the future landscape of life sciences. As journeys unfold in the fast-evolving biopharma space, the contributions of these seasoned advisors are bound to create significant ripples of influence and foster progressive innovation.